These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

430 related items for PubMed ID: 24568585

  • 1. Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease.
    Jain P, Karthikeyan C, Moorthy NS, Waiker DK, Jain AK, Trivedi P.
    Curr Drug Targets; 2014 May; 15(5):539-50. PubMed ID: 24568585
    [Abstract] [Full Text] [Related]

  • 2. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing.
    Fedorov O, Huber K, Eisenreich A, Filippakopoulos P, King O, Bullock AN, Szklarczyk D, Jensen LJ, Fabbro D, Trappe J, Rauch U, Bracher F, Knapp S.
    Chem Biol; 2011 Jan 28; 18(1):67-76. PubMed ID: 21276940
    [Abstract] [Full Text] [Related]

  • 3. Structural Basis for the Selective Inhibition of Cdc2-Like Kinases by CX-4945.
    Lee JY, Yun JS, Kim WK, Chun HS, Jin H, Cho S, Chang JH.
    Biomed Res Int; 2019 Jan 28; 2019():6125068. PubMed ID: 31531359
    [Abstract] [Full Text] [Related]

  • 4. Regulation of influenza A virus mRNA splicing by CLK1.
    Artarini A, Meyer M, Shin YJ, Huber K, Hilz N, Bracher F, Eros D, Orfi L, Keri G, Goedert S, Neuenschwander M, von Kries J, Domovich-Eisenberg Y, Dekel N, Szabadkai I, Lebendiker M, Horváth Z, Danieli T, Livnah O, Moncorgé O, Frise R, Barclay W, Meyer TF, Karlas A.
    Antiviral Res; 2019 Aug 28; 168():187-196. PubMed ID: 31176694
    [Abstract] [Full Text] [Related]

  • 5. Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing.
    Debdab M, Carreaux F, Renault S, Soundararajan M, Fedorov O, Filippakopoulos P, Lozach O, Babault L, Tahtouh T, Baratte B, Ogawa Y, Hagiwara M, Eisenreich A, Rauch U, Knapp S, Meijer L, Bazureau JP.
    J Med Chem; 2011 Jun 23; 54(12):4172-86. PubMed ID: 21615147
    [Abstract] [Full Text] [Related]

  • 6. Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
    Lindberg MF, Meijer L.
    Int J Mol Sci; 2021 Jun 03; 22(11):. PubMed ID: 34205123
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Kororamides, Convolutamines, and Indole Derivatives as Possible Tau and Dual-Specificity Kinase Inhibitors for Alzheimer's Disease: A Computational Study.
    Llorach-Pares L, Nonell-Canals A, Avila C, Sanchez-Martinez M.
    Mar Drugs; 2018 Oct 16; 16(10):. PubMed ID: 30332805
    [Abstract] [Full Text] [Related]

  • 11. Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands.
    Murár M, Dobiaš J, Šramel P, Addová G, Hanquet G, Boháč A.
    Eur J Med Chem; 2017 Jan 27; 126():754-761. PubMed ID: 27940419
    [Abstract] [Full Text] [Related]

  • 12. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
    Tazarki H, Zeinyeh W, Esvan YJ, Knapp S, Chatterjee D, Schröder M, Joerger AC, Khiari J, Josselin B, Baratte B, Bach S, Ruchaud S, Anizon F, Giraud F, Moreau P.
    Eur J Med Chem; 2019 Mar 15; 166():304-317. PubMed ID: 30731399
    [Abstract] [Full Text] [Related]

  • 13. Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype.
    Walter A, Chaikuad A, Helmer R, Loaëc N, Preu L, Ott I, Knapp S, Meijer L, Kunick C.
    PLoS One; 2018 Mar 15; 13(5):e0196761. PubMed ID: 29723265
    [Abstract] [Full Text] [Related]

  • 14. Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.
    Tahtouh T, Elkins JM, Filippakopoulos P, Soundararajan M, Burgy G, Durieu E, Cochet C, Schmid RS, Lo DC, Delhommel F, Oberholzer AE, Pearl LH, Carreaux F, Bazureau JP, Knapp S, Meijer L.
    J Med Chem; 2012 Nov 08; 55(21):9312-30. PubMed ID: 22998443
    [Abstract] [Full Text] [Related]

  • 15. Mobilization of a splicing factor through a nuclear kinase-kinase complex.
    Aubol BE, Keshwani MM, Fattet L, Adams JA.
    Biochem J; 2018 Feb 14; 475(3):677-690. PubMed ID: 29335301
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice.
    Naert G, Ferré V, Meunier J, Keller E, Malmström S, Givalois L, Carreaux F, Bazureau JP, Maurice T.
    Eur Neuropsychopharmacol; 2015 Nov 14; 25(11):2170-82. PubMed ID: 26381812
    [Abstract] [Full Text] [Related]

  • 18. Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.
    Mariano M, Hartmann RW, Engel M.
    Eur J Med Chem; 2016 Apr 13; 112():209-216. PubMed ID: 26896709
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.